Vitamin d binding protein in the clinical management of hematopoietic stem cell transplantation
AssigneeChildren's Hospital Medical Center
InventorsStella M. Davies, Nathan Luebbering
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for improving the clinical management of hematopoietic stem cell transplant (HSCT) recipients by identifying patients at increased risk for non-relapse mortality or a transplantation associated adverse event using serum or plasma levels of vitamin D binding protein (VDBP) as a biomarker and related methods of monitoring therapy using same and the use of VDBP in therapy to prevent non-relapse mortality or a transplantation associated adverse event in a HSCT recipient, especially recipients identified as being at high risk.
Claims13
A method for identifying a hematopoietic stem cell transplant (HSCT) recipient at increased risk for post-HSCT non-relapse mortality or a transplantation associated adverse event, the method comprising determining ex vivo or in vitro a level of vitamin D binding protein (VDBP) in a serum or plasma sample obtained from the HSCT recipient, wherein a level of VDBP below a predetermined threshold identifies the HSCT recipient as being at increased risk of non-relapse mortality or a transplantation associated adverse event.
A method for monitoring a therapy of an HSCT recipient, the method comprising determining ex vivo or in vitro a level of VDBP in a serum or plasma sample obtained from the HSCT recipient, wherein a level of VDBP below a predetermined threshold indicates that the recipient is at increased risk of non-relapse mortality or a transplantation associated adverse event and that the therapy should be adjusted.
A method of treating an HSCT recipient, the method comprising administering purified or recombinant human VDBP to the recipient following transplantation.
13-16. (canceled)
Dependencies are inferred from the claim text.